Skip to main content

Table 1 Baseline characteristics and 28-day mortality of PROWESS patients by baseline protein C level and treatment group

From: Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

Parameter Baseline protein C ≤ 40% of normal Baseline protein C 41–80% of normal Baseline protein C >80% of normal
  Placebo (n = 285) DrotAA (n = 330) Placebo (n = 385) DrotAA (n = 379) Placebo (n = 105) DrotAA (n = 90)
APACHE II score* 26.1 ± 8.1 25.6 ± 7.7 24.3 ± 7.8 23.9 ± 7.5 23.9 ± 7.3 23.8 ± 6.7
Age (years) 61.4 ± 16.9 60.9 ± 17.1 60.0 ± 16.7 59.9 ± 17.8 61.9 ± 14.6 61.4 ± 16.4
Log IL-6* 7.4 ± 2.1 7.5 ± 2.2 6.1 ± 2.0 6.2 ± 2.0 4.7 ± 1.8 4.7 ± 1.7
Urosepsis (%) 9.8 10.3 12.2 8.7 3.8 14.4
Comorbiditesa (%)** 16.5 15.5 20.0 19.8 35.2 34.4
Dependenciesb (%)** 25.3 21.8 29.6 29.3 38.1 33.3
Septic shock (%)** 76.8 80.6 72.2 66.0 59.0 55.6
28-day mortality (%) 41.8 27.6 24.9 24.0 26.7 15.6
  1. DrotAA, drotrecogin alfa (activated). Patients were prospectively categorized on the basis of their baseline protein C activity levels (normal, >80%; deficient, 41–80% of normal; and severely deficient, ≤ 40% of normal). aAny chronic health points from the (APACHE) II classification system. bPatient considered dependent if they were dependent in one or more activities on the Activities of Daily Living scale [16]. *Significantly different between protein C classes (P < 0.05) using Spearman rank-correlation with baseline protein C levels. **Significant (P < 0.05) association with baseline protein C levels using Wilcoxon rank-sum tests comparing the "yes" versus "no" classifications